These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 36614224)

  • 1. Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments.
    Makowska K; Nowaczyk J; Blicharz L; Waśkiel-Burnat A; Czuwara J; Olszewska M; Rudnicka L
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
    Nakashima C; Otsuka A; Kabashima K
    Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
    Shih PY; Li CJ; Yong SB
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets.
    Fania L; Moretta G; Antonelli F; Scala E; Abeni D; Albanesi C; Madonna S
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 31 and skin diseases: A systematic review.
    Gangemi S; Quartuccio S; Casciaro M; Trapani G; Minciullo PL; Imbalzano E
    Allergy Asthma Proc; 2017 Nov; 38(6):401-408. PubMed ID: 29046191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review.
    Saleem MD; Oussedik E; D'Amber V; Feldman SR
    J Dermatolog Treat; 2017 Nov; 28(7):591-599. PubMed ID: 28145790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice.
    Choi H; Kim DJ; Nam S; Lim S; Hwang JS; Park KS; Hong HS; Won Y; Shin MK; Chung E; Son Y
    J Dermatol Sci; 2018 Mar; 89(3):248-257. PubMed ID: 29269174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Emerging Therapies for Atopic Dermatitis in the Elderly.
    Teng Y; Zhong H; Yang X; Tao X; Fan Y
    Clin Interv Aging; 2023; 18():1641-1652. PubMed ID: 37810952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.
    Furue M; Yamamura K; Kido-Nakahara M; Nakahara T; Fukui Y
    Allergy; 2018 Jan; 73(1):29-36. PubMed ID: 28670717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advancements in the Atopic Dermatitis Mechanism.
    Savva M; Papadopoulos NG; Gregoriou S; Katsarou S; Papapostolou N; Makris M; Xepapadaki P
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):84. PubMed ID: 38420827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Pathogenesis and Therapy of Atopic Dermatitis.
    Li H; Zhang Z; Zhang H; Guo Y; Yao Z
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):324-338. PubMed ID: 34338977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment.
    Alsabbagh M; Ismaeel A
    Acta Dermatovenerol Alp Pannonica Adriat; 2022 Mar; 31(1):13-31. PubMed ID: 35339129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.
    Honstein T; Werfel T
    Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):386-394. PubMed ID: 32452891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of biologics in atopic dermatitis.
    Wu J; Guttman-Yassky E
    Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
    [No Abstract]   [Full Text] [Related]  

  • 17. Gamisasangja-tang suppresses pruritus and atopic skin inflammation in the NC/Nga murine model of atopic dermatitis.
    Park BK; Park YC; Jung IC; Kim SH; Choi JJ; Do M; Kim SY; Jin M
    J Ethnopharmacol; 2015 May; 165():54-60. PubMed ID: 25721805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives.
    Pareek A; Kumari L; Pareek A; Chaudhary S; Ratan Y; Janmeda P; Chuturgoon S; Chuturgoon A
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the effects on pruritus by novel treatments for atopic dermatitis.
    Bonnekoh H; Butze M; Metz M
    J Dtsch Dermatol Ges; 2022 Feb; 20(2):150-156. PubMed ID: 34958173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future treatment options for atopic dermatitis - small molecules and beyond.
    Schäkel K; Döbel T; Bosselmann I
    J Dermatol Sci; 2014 Feb; 73(2):91-100. PubMed ID: 24360854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.